Barrett's Esophagus

Follow-up esophagogastric junction sampling for intestinal metaplasia may not be necessary in patients after complete and successful eradication therapy for Barrett’s esophagus, researchers reported.

Researchers have identified a cell signaling pathway involved in the development of Barrett’s esophagus and esophageal adenocarcinoma, which may lead to possible life-saving therapy for this aggressive cancer.

Between 2012 and 2019, esophageal cancer rates nearly doubled and prevalence of Barrett’s esophagus increased by 50% among adults aged 45 to 64 years, according to researchers.

The American College of Gastroenterology recently revised its clinical guidelines for Barrett’s esophagus.

The AGA has issued a clinical practice update on de-prescribing proton pump inhibitors, according to an article in Gastroenterology.

In this Endo-Sketch, a Healio video series on clinical conditions named after famous colleagues, Klaus Mergener, MD, of the University of Washington School of Medicine, discusses the origin of Barrett’s esophagus.

The ACG issued revised clinical guidelines for the diagnosis and management of patients with Barrett’s esophagus, which were published in the American Journal of Gastroenterology.

A novel risk model predicted treatment complexity among patients with Barrett’s esophagus following initial radiofrequency ablation treatment, according to research published in Clinical Gastroenterology and Hepatology.

A family history of Barrett’s esophagus or esophageal adenocarcinoma may serve as an early identifier of patients at a high risk for esophageal adenocarcinoma-related mortality.

Progress in the non-endoscopic detection for Barrett’s esophagus may lead to increased identification of those at risk for esophageal adenocarcinoma, according to opinions published in Annals of Internal Medicine.